The Technical Analyst
Adamas Pharmaceuticals [ADMS]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Adamas Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $8.22
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-02-09 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.03 - 8.41 ( +/- 2.30%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-24 | Mahoney David L | Sell | 112 781 | Common Stock |
| 2021-11-24 | Mahoney David L | Sell | 10 000 | Stock Option (Right to Buy) |
| 2021-11-24 | Mahoney David L | Sell | 40 000 | Stock Option (Right to Buy) |
| 2021-11-24 | Mahoney David L | Sell | 10 000 | Stock Option (Right to Buy) |
| 2021-11-24 | Mahoney David L | Sell | 10 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 2 100 832 | Sell: 2 425 856 |
Forecast:
01:40 - $7.90
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.22 (0.00% ) |
| Volume | 3.15 mill |
| Avg. Vol. | 1.339 mill |
| % of Avg. Vol | 235.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADMS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ADMS
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Last 10 Buy Signals
Latest Press Releases
2021-10-28 14:25:00 - Press Release
Shareholder Investigation: Halper Sadeh Llp Investigates Ftsi, Umpq, Flxn, Adms; Shareholders Are Encouraged To Contact The Firm
New york, oct. 28, 2021 /prnewswire/ -- halper sadeh llp, a global investor rights law firm, announces it is investigating the following companies: fts international, inc. (nyse: ftsi) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to profrac holdings, llc for $26.52 per share in cash. if you are an fts international shareholder, click here to learn more about your rights and options.
2021-10-26 21:48:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Adms, Flxn, Azpn, And Ebmt Shareholders About Its Ongoing Investigations
New york, oct. 26, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weisslaw llp305 broadway, 7th floor new york, ny 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com adamas pharmaceuticals, inc. (nasdaq: adms) weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of adamas pharmaceuticals, inc. (nasdaq: adms) in connection with the proposed acquisition of the company by supernus pharmaceuticals, inc. under the terms of the agreement, adms shareholders will receive $8...
2021-10-15 22:46:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Adamas Pharmaceuticals, Inc. - Adms
New york, oct. 15, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018-2020 iss securities class action services report and headquartered at the empire state building in new york city, is investigating adamas pharmaceuticals, inc. ("adms" or the "company") (adms) relating to its proposed acquisition by supernus pharmaceuticals, inc. under the terms of the agreement, adms shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own. the investigation focuses on whether adamas pharmaceuticals, inc. and its board of directors violated securities laws and/or breached their fiduciary duties to the company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
2021-10-11 15:30:00 - Press Release
Shareholder Alert: Levi & Korsinsky, Llp Notifies Investors Of An Investigation Into The Fairness Of The Merger Of Adamas Pharmaceuticals, Inc. With Supernus Pharmaceuticals, Inc.
New york, new york--(newsfile corp. - october 11, 2021) - the following statement is being issued by levi & korsinsky, llp:to: all persons or entities who purchased adamas pharmaceuticals, inc. (nasdaq: adms) ("adamas" or the "company") stock prior to october 11, 2021. to view an enhanced version of this graphic, please visit:
2021-10-11 13:37:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Adamas Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Transaction With Supernus
Milwaukee, oct. 11, 2021 /prnewswire/ -- ademi llp is investigating adamas (nasdaq: adms), for possible breaches of fiduciary duty and other violations of law in its transaction with supernus. click here to learn how to join the action: https://www.ademilaw.com/case/adamas-pharmaceuticals-inc or call guri ademi toll-free at 866-264-3995.
Latest News
2022-12-09 08:10:38 - Market Watch
Lab-grown diamond maker Adamas One raises $11 mln in IPO
Adamas One Corp. JEWL, said it priced 2.45 million shares at $4.50 a share for proceeds of $11 million in its initial public offering for trading on Friday on the Nasdaq. The Scottsdale, Ariz.
2021-10-15 22:46:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Adamas Pharmaceuticals, Inc. - ADMS
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Adamas Pharmaceuticals, Inc. ("ADMS" or the "Company") (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own. The investigation focuses on whether Adamas Pharmaceuticals, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
2021-10-11 15:30:00 - Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Adamas Pharmaceuticals, Inc. with Supernus Pharmaceuticals, Inc.
New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") stock prior to October 11, 2021. To view an enhanced version of this graphic, please visit:
2021-10-11 13:37:00 - PRNewsWire
Shareholder Alert: Ademi LLP investigates whether Adamas Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Supernus
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus. Click here to learn how to join the action: https://www.ademilaw.com/case/adamas-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
2021-10-11 12:02:20 - InvestorPlace
ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News
ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals Acquisition News appeared first on InvestorPlace.
2021-10-11 11:39:00 - Business Wire
Adamas Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Adamas Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADMS
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $8.10 per share in cash plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash is fair to Adamas shareholders. Halper Sadeh encourages Adamas shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halpe
2021-10-11 08:53:24 - Benzinga
Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal consideration includes $8.10 per share in cash ($400 million) and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash.
2021-10-11 08:38:21 - Pulse2
ADMS Stock: Why It Substantially Increased Today
The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 70% pre-market today. This is why it happened.
2021-10-08 16:15:00 - Business Wire
Adamas Announces New Employment Inducement Grants
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company's common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of
2021-10-01 09:15:00 - Business Wire
Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year's UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories